The SeroCoV study is a household-based cross-sectional study that aims to estimate the prevalence of anti-SARS-CoV-2 IgG antibodies and associated risk factors in three African countries: Burkina Faso, Ghana, and Madagascar. Commmunity members from altogether 5 urban sites that are 10 years or older are recruited using using a two-stage cluster sampling approach. The primary outcome measure is the proportion of the population that has been exposed to the virus and have developed anti SARS-CoV-2 antibodies; measured by Enzyme-linked Immunosorbent Assays (ELISAs).
Teams at partner institutions:
Team Hamburg: Eva Lorenz, Christina Deschermeier, Ben Rushton, Jenny Kettenbeil, Wibke Loag.
Team Burkina Faso: Aurélia Souares, Ali Sié, Thierry Ouedraogo, Valentin Buodo.
Team Ghana: John Amuasi, Anthony Afum-Adjei Awuah, Christian Obirikorang.
Team Madagascar: Daniela Fusco, Rivo Rakotoarivelo, Dominik Benke, Yannick Hoeppner